Comparative Pharmacology
Head-to-head clinical analysis: INDERAL versus PINDOLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERAL versus PINDOLOL.
INDERAL vs PINDOLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-adrenergic receptor antagonist; competes with catecholamines for binding at beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure.
Pindolol is a nonselective beta-adrenergic receptor antagonist with intrinsic sympathomimetic activity (ISA). It blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Its ISA partially stimulates beta receptors, leading to less bradycardia and bronchoconstriction than other nonselective beta-blockers.
Hypertension: 40 mg orally twice daily; increase as needed up to 640 mg/day. Angina: 80-320 mg orally daily in divided doses. Migraine prophylaxis: 80 mg orally daily in divided doses; up to 160-240 mg/day. Arrhythmias: 10-30 mg orally 3-4 times daily. IV: 1-3 mg IV bolus at 1 mg/min; may repeat after 2 min.
5 mg orally twice daily, titrated to 10-60 mg/day in divided doses; maximum 60 mg/day.
None Documented
None Documented
Clinical Note
moderateBopindolol + Digoxin
"Bopindolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateBopindolol + Digitoxin
"Bopindolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderatePindolol + Digitoxin
"Pindolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateBopindolol + Deslanoside
"Bopindolol may increase the bradycardic activities of Deslanoside."
3-6 hours (terminal). Clinical context: half-life increases with chronic dosing due to saturable hepatic metabolism; in cirrhosis, half-life may be prolonged to 10-23 hours.
The terminal elimination half-life of pindolol is 3-4 hours. However, due to its intrinsic sympathomimetic activity, the clinical duration of beta-blockade is longer, allowing for once-daily dosing in some patients.
Renal: 96-99% as metabolites (active 4-hydroxypropranolol and conjugates), <1% unchanged. Biliary/fecal: minimal.
Pindolol is excreted primarily via the kidneys (renal clearance), with 60-65% of the dose eliminated unchanged in urine. Approximately 30-40% is metabolized in the liver, and biliary/fecal excretion accounts for less than 5%.
Category C
Category A/B
Beta-Blocker
Beta-Blocker